242 related articles for article (PubMed ID: 35029056)
1. Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.
Usman MS; Khan MS; Fonarow GC; Greene SJ; Friede T; Vaduganathan M; Filippatos G; Coats AJS; Anker SD; Butler J
ESC Heart Fail; 2022 Apr; 9(2):885-893. PubMed ID: 35029056
[TBL] [Abstract][Full Text] [Related]
2. The fragility index and reverse fragility index of FDA investigational device exemption trials in spinal fusion surgery: a systematic review.
Proal JD; Moon AS; Kwon B
Eur Spine J; 2024 May; ():. PubMed ID: 38802596
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Robustness of the Landmark Cardiovascular Outcome Trials of Antidiabetic Drugs - A Systematic Review.
Bose D; Konwar M
Curr Diabetes Rev; 2022; 18(6):e140921196472. PubMed ID: 34521330
[TBL] [Abstract][Full Text] [Related]
4. Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis.
Vukadinović D; Abdin A; Anker SD; Rosano GMC; Mahfoud F; Packer M; Butler J; Böhm M
Eur J Heart Fail; 2022 Sep; 24(9):1625-1632. PubMed ID: 35730422
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.
Chen HB; Yang YL; Meng RS; Liu XW
ESC Heart Fail; 2023 Apr; 10(2):1231-1241. PubMed ID: 36702979
[TBL] [Abstract][Full Text] [Related]
6. Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies.
Figueroa-Parra G; Putman MS; Crowson CS; Duarte-García A
Lupus Sci Med; 2024 Jan; 11(1):. PubMed ID: 38199863
[TBL] [Abstract][Full Text] [Related]
7. The statistical fragility of intramedullary reaming in tibial nail fixation: a systematic review.
Minhas A; Berkay F; Ehlers CB; Froehle AW; Krishnamurthy AB
Eur J Trauma Emerg Surg; 2023 Dec; 49(6):2347-2354. PubMed ID: 36879152
[TBL] [Abstract][Full Text] [Related]
8. Fragility of cardiovascular outcome trials (CVOTs) examining nutrition interventions among patients with diabetes mellitus: a systematic review of randomized controlled trials.
Taouktsi N; Papageorgiou ST; Tousinas G; Papanikolopoulou S; Grammatikopoulou MG; Giannakoulas G; Goulis DG
Hormones (Athens); 2022 Dec; 21(4):665-681. PubMed ID: 36129664
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.
Tomasoni D; Fonarow GC; Adamo M; Anker SD; Butler J; Coats AJS; Filippatos G; Greene SJ; McDonagh TA; Ponikowski P; Rosano G; Seferovic P; Vaduganathan M; Voors AA; Metra M
Eur J Heart Fail; 2022 Mar; 24(3):431-441. PubMed ID: 34894038
[TBL] [Abstract][Full Text] [Related]
11. The fragility of statistical findings in the reverse total shoulder arthroplasty literature: a systematic review of randomized controlled trials.
Yendluri A; Chiang JJ; Linden GS; Megafu MN; Galatz LM; Parsons BO; Parisien RL
J Shoulder Elbow Surg; 2024 Jul; 33(7):1650-1658. PubMed ID: 38281679
[TBL] [Abstract][Full Text] [Related]
12. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
[TBL] [Abstract][Full Text] [Related]
13. Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?
Mukhopadhyay P; Sanyal D; Chatterjee P; Pandit K; Ghosh S
Endocr Pract; 2022 Aug; 28(8):795-801. PubMed ID: 35569736
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
[TBL] [Abstract][Full Text] [Related]
15. The fragility and reverse fragility indices of proximal humerus fracture randomized controlled trials: a systematic review.
Kyriakides PW; Schultz BJ; Egol K; Leucht P
Eur J Trauma Emerg Surg; 2022 Dec; 48(6):4545-4552. PubMed ID: 34056677
[TBL] [Abstract][Full Text] [Related]
16. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
17. The Statistical Fragility of Tranexamic Acid Use in the Orthopaedic Surgery Literature: A Systematic Review of Randomized Controlled Trials.
Brown AN; Yendluri A; Lawrence KW; Cordero JK; Moucha CS; Hayden BL; Parisien RL
J Am Acad Orthop Surg; 2024 Jun; 32(11):508-515. PubMed ID: 38574390
[TBL] [Abstract][Full Text] [Related]
18. An analysis of randomized controlled trials on anal fistula conducted between 2000 and 2020 based on the Fragility Index and Reverse Fragility Index.
Placer-Galán C; Enriquez-Navascués JM; Lopetegui AE; Ansorena YS
Colorectal Dis; 2023 Aug; 25(8):1572-1577. PubMed ID: 37400967
[TBL] [Abstract][Full Text] [Related]
19. Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
Ferreira JP; Pimenta J; Moura B; Aguiar C; Franco F
ESC Heart Fail; 2022 Dec; 9(6):4344-4347. PubMed ID: 36004699
[TBL] [Abstract][Full Text] [Related]
20. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
